
OpGen OPGN
Quarterly report 2025-Q3
added 11-19-2025
OpGen Total Non Current Liabilities 2011-2026 | OPGN
Annual Total Non Current Liabilities OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 21.2 M | 1.19 M | 1.26 M | 429 K | 545 K | 1.38 M | 4.7 M | 2.23 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | 429 K | 4.12 M |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
3.29 B | $ 114.78 | -0.61 % | $ 34.9 B | ||
|
Biodesix
BDSX
|
62.1 M | $ 15.7 | 4.18 % | $ 2.04 B | ||
|
Biomerica
BMRA
|
1.57 M | $ 2.15 | -0.83 % | $ 4.94 M | ||
|
BioNano Genomics
BNGO
|
16.4 M | $ 1.16 | -3.33 % | $ 6.32 M | ||
|
Burning Rock Biotech Limited
BNR
|
61.1 M | $ 16.33 | 0.8 % | $ 176 M | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 18.12 | -1.04 % | $ 966 M | ||
|
Celcuity
CELC
|
69.2 K | $ 114.33 | 1.5 % | $ 5.35 B | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Co-Diagnostics
CODX
|
574 K | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 166.88 | -4.03 % | $ 8.27 B | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 25.0 | 0.64 % | $ 694 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
Danaher Corporation
DHR
|
26.9 B | $ 191.23 | 0.06 % | $ 136 B | ||
|
DexCom
DXCM
|
1.15 B | $ 63.01 | 1.26 % | $ 24.6 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 16.56 | -1.55 % | $ 501 M | ||
|
Guardant Health
GH
|
91.4 M | $ 90.84 | -3.19 % | $ 11.4 B | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 111.1 | -2.71 % | $ 9.16 B | ||
|
Interpace Biosciences
IDXG
|
10 M | $ 1.92 | -1.92 % | $ 8.49 M | ||
|
Illumina
ILMN
|
2.04 B | $ 126.95 | -0.34 % | $ 20.2 B | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
IQVIA Holdings
IQV
|
13 B | $ 169.58 | -2.12 % | $ 29.2 B | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 274.35 | 0.23 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 75.67 | -0.57 % | $ 5.11 B | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 494.14 | -0.84 % | $ 14.3 B | ||
|
Mettler-Toledo International
MTD
|
1.61 B | $ 1 256.28 | -0.29 % | $ 25.9 B | ||
|
Myriad Genetics
MYGN
|
107 M | $ 4.76 | 0.11 % | $ 441 M | ||
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
ENDRA Life Sciences
NDRA
|
843 K | $ 4.57 | -2.46 % | $ 3.6 M | ||
|
NeoGenomics
NEO
|
435 M | $ 7.98 | -0.25 % | $ 1.02 B | ||
|
Neogen Corporation
NEOG
|
19.6 M | $ 9.51 | 1.01 % | $ 2.06 B | ||
|
National Research Corporation
NRC
|
39.6 M | $ 17.43 | 1.6 % | $ 390 M | ||
|
Natera
NTRA
|
124 M | $ 204.77 | -1.54 % | $ 20.2 B | ||
|
Pacific Biosciences of California
PACB
|
43.9 M | $ 1.41 | 5.05 % | $ 423 M | ||
|
Koninklijke Philips N.V.
PHG
|
8.08 B | $ 27.02 | -0.33 % | $ 20 B | ||
|
Precipio
PRPO
|
1.9 M | $ 26.84 | 5.67 % | $ 43.1 M | ||
|
Personalis
PSNL
|
639 K | $ 6.64 | 0.84 % | $ 393 M | ||
|
RadNet
RDNT
|
1.09 B | $ 55.13 | 0.62 % | $ 4.15 B | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M |